Article

The Anti-VEGF Aptamer Approach: The Macugen Collaborative Trial

Recent results of clinical trials of the anti-VEGF aptamer Macugen (pegaptanibsodium are extremely promising for patients with choroidal neovascularization,said Carmen Puliafito, MD, MBNA, chairman of the Bascom Palmer Eye Institute,Miami.

Related Videos
2 experts are featured in this series.
Related Content
Women advised to take part in Dry January to reduce dry eye risk
January 2nd 2025

Women advised to take part in Dry January to reduce dry eye risk

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Emerging insights into ocular immune-related diseases and treatment options
January 1st 2025

Emerging insights into ocular immune-related diseases and treatment options

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

What increased depth of focus can mean to your monofocal IOL patients
December 31st 2024

What increased depth of focus can mean to your monofocal IOL patients

Wrapping up another year in eye care: 2024 in review from Ophthalmology Times Europe
December 30th 2024

Wrapping up another year in eye care: 2024 in review from Ophthalmology Times Europe

© 2025 MJH Life Sciences

All rights reserved.